Figure 3

Postprandial percent decrease in FMD [(postprandial FMD-fasting FMD) × 100/fasting FMD] in the control, acarbose and nateglinide groups after 12 weeks of treatment. The postprandial decrease in FMD was significantly suppressed in the acarbose group, compared to the control and nateglinide groups. The postprandial FMD decrease in nateglinide group was also suppressed compared to the control group.